ストックスクリーナーアプリを入手
7.67
1.99%
0.15
アフターアワーズ：
7.66
-0.010
-0.13%
前日終値:
$7.52
開ける：
$7.47
24時間の取引高:
2.02M
Relative Volume:
1.45
時価総額：
$464.75M
収益：
$65,400
当期純損益:
$-46.34M
株価収益率:
-8.337
EPS:
-0.92
ネットキャッシュフロー:
$-38.74M
1週間 パフォーマンス:
+12.13%
1か月 パフォーマンス:
-26.74%
6か月 パフォーマンス:
-26.88%
1年 パフォーマンス:
+40.99%
1日の値動き範囲:
$7.39
$7.84
1週間の範囲:
$6.76
$7.84
52週間の値動き範囲:
$3.61
$13.85
CorMedix Inc Stock (CRMD) Company Profile
名前
CorMedix Inc
セクター
電話
908-517-9500
住所
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
CRMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
7.67 | 464.75M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-07 | 開始されました | Leerink Partners | Outperform |
| 2025-01-13 | 開始されました | D. Boral Capital | Buy |
| 2024-08-26 | 開始されました | Rodman & Renshaw | Buy |
| 2023-08-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-02-17 | 開始されました | Needham | Buy |
| 2020-09-29 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-09-21 | 開始されました | Truist | Buy |
| 2019-12-18 | 開始されました | B. Riley FBR | Buy |
| 2019-03-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-12-06 | 開始されました | ROTH Capital | Buy |
| 2017-09-25 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-08-10 | 繰り返されました | Rodman & Renshaw | Buy |
| 2017-05-05 | 繰り返されました | Rodman & Renshaw | Buy |
| 2016-11-11 | 繰り返されました | FBR & Co. | Outperform |
| 2016-03-17 | 繰り返されました | FBR Capital | Outperform |
| 2016-03-03 | 開始されました | FBR Capital | Outperform |
| 2015-11-16 | 繰り返されました | ROTH Capital | Neutral |
| 2015-10-29 | 繰り返されました | ROTH Capital | Neutral |
| 2015-05-06 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2014-12-08 | 繰り返されました | ROTH Capital | Buy |
| 2011-10-03 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
CorMedix Inc (CRMD) 最新ニュース
Investors in CorMedix (NASDAQ:CRMD) have seen decent returns of 81% over the past five years - Yahoo Finance
RBC stays bullish on CorMedix as Q1 preliminary revenue reassures on near-term - Yahoo Finance
CorMedix expects Q1 sales above estimates, lifts H1 outlook - MSN
CorMedix reports preliminary Q1 revenue $39M, consensus $32.2M. - TipRanks
CorMedix at Needham Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
CorMedix at Needham Conference: Strategic Growth and Challenges - Investing.com
CorMedix Stock Rises After Preliminary Q1 Results Exceeds Expectations: Retail’s Elated - MSN
CRMD Soars 19.40% as CorMedix Announces Preliminary Q1 Results and Raises H1 Guidance, But Will the Momentum Continue? - RagingBull
CorMedix Inc. Raises Financial Guidance for First Half of 2025 - MarketScreener
CorMedix Sees Q1 Net Sales of $39 Million; Boosts H1 Net Sales Guidance - MarketScreener
Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance - The Manila Times
CorMedix Logs Q1 Prel. Revenue Of $39 Mln - Nasdaq
CorMedix reports strong preliminary Q1 revenue and EBITDA - Investing.com
CorMedix Smashes Expectations: $39M Q1 Revenue and Massive Guidance Boost Signals Growth Acceleration - Stock Titan
CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
CorMedix CEO Sets Stage for Strategic Updates at Elite Needham Healthcare Conference - Stock Titan
CorMedix Inc. (NASDAQ:CRMD) Q4 2024 Earnings Call Transcript - Insider Monkey
CorMedix Inc. Reports Record Q4 Earnings and Growth - TipRanks
CorMedix: A Fair-Priced Biotech Company With A Bright Future - Seeking Alpha
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of ... - Bluefield Daily Telegraph
Institutions along with individual investors who hold considerable shares inCorMedix Inc. (NASDAQ:CRMD) come under pressure; lose 35% of holdings value - Yahoo Finance
CorMedix targets $50M-$60M revenue for H1 2025 with DefenCath growth - MSN
CorMedix Inc.'s (NASDAQ:CRMD) 35% loss last week hit both individual investors who own 56% as well as institutions - simplywall.st
Lost Money on CorMedix Inc.(CRMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Kirby McInerney LLP Announces Investigation Against CorMedix Inc. (CRMD) on Behalf of Investors - GlobeNewswire
The Hidden Risks Behind CorMedix's First Profitable Quarter (NASDAQ:CRMD) - Seeking Alpha
CorMedix Inc (NASDAQ:CRMD) Order Delay - FXDailyReport.Com
Long Term Trading Analysis for (CRMD) - news.stocktradersdaily.com
INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC - GlobeNewswire
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It - Asianet Newsable
Cormedix Inc (CRMD) Q4 2024 Earnings Call Highlights: A Profitable Quarter Amidst Strategic ... By GuruFocus - Investing.com Canada
CorMedix Inc. Achieves Profitability with DefenCath Launch - TipRanks
Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target By Investing.com - Investing.com Australia
CorMedix: Q4 Earnings Snapshot - MySA
Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target - Investing.com
CorMedix (CRMD) Q4 2024 Earnings Call Transcript - AOL.com
CorMedix earnings beat by $0.05, revenue topped estimates - Investing.com Canada
Needham Cuts CorMedix's Price Target to $12 from $18, Keeps Buy Rating - MarketScreener
Cormedix: Positive Outlook with Strategic Advancements and Strong Financial Performance - TipRanks
CorMedix Inc. (CRMD) Takes a Hit: What’s Behind the 31% Plunge? - RagingBull
Nasdaq Gains 50 Points; US New Home Sales Rise In February - Benzinga
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It Off - MSN
Earnings call transcript: CorMedix Q4 2024 reports first profit, stock plunges - Investing.com Australia
CorMedix shares tumble after order delay By Investing.com - Investing.com Philippines
CorMedix shares tumble after order delay - Investing.com
Earnings call transcript: CorMedix Q4 2024 reports first profit, stock plunges By Investing.com - Investing.com South Africa
CorMedix Inc (CRMD) 財務データ
収益
当期純利益
現金流量
EPS
CorMedix Inc (CRMD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Todisco Joseph | Chief Executive Officer |
Apr 01 '25 |
Option Exercise |
3.38 |
59,170 |
199,995 |
530,721 |
| Mistry Erin | EVP, Chief Commercial Officer |
Oct 31 '24 |
Buy |
9.99 |
1,500 |
14,985 |
52,011 |
| Hurlburt Elizabeth | EVP |
Nov 14 '24 |
Option Exercise |
4.48 |
140,027 |
627,727 |
185,424 |
| Hurlburt Elizabeth | EVP |
Nov 14 '24 |
Sale |
11.18 |
140,027 |
1,565,670 |
45,397 |
2.51%
大文字化:
|
ボリューム (24 時間):